Horizon Discovery divests animal models business to Envigo
Envigo enters CRISPR gene-edited research model field with the addition of Horizon’s business
12 Nov 2019
Industry news
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation technologies, has announced an agreement to divest the group’s animal research models business unit to Envigo.
The divestment forms part of Horizon’s strategy to refocus on high growth areas within its core market and is expected to be completed within 30-45 days, subject to customary closing conditions. Already a well-established supplier of gene editing and gene modulation reagents, libraries and gene-edited cell models, Horizon is expanding its cell-based screening services to support drug discovery and development workflows, from target identification to patient stratification, and engineered CHO cell lines for biotherapeutic manufacture.
Horizon’s research models business unit, which provides genetically engineered models from its premises in Boyertown, Pennsylvania and St Louis, Missouri, USA, will be transferred to Envigo ownership, including assets and employees. The business unit uses Horizon’s gene editing expertise to produce customized models with clinically relevant gene deletions, insertions and other modifications, which are then used as pre-clinical models for human genetic disease during drug discovery and development. The two companies will collaborate to ensure continuity and enable all customers to access CRISPR-edited research models for screening and other applications. Customers should continue to work with their contacts at Horizon and Envigo as they have done to date, for all projects.
Envigo, which is headquartered in the US, has more than 1,200 employees in more than 20 locations across North America and Europe. The company provides a broad range of standard research models to the pharmaceutical and biotechnology industries, government, academia and other life science organizations.
Terry Pizzie, Chief Executive Officer of Horizon Discovery, commented: “We are pleased to announce this transaction with a strong commercial partner, Envigo, which will provide an opportunity for the research models business to flourish within a larger, market-leading company and also deliver continuity for its many customer relationships. Envigo will bring a dedicated sales channel to the organization to super-charge the positive work already done by the Horizon sales team over the last months. Horizon will collaborate with Envigo to provide access to our experience and expertise in generating CRISPR-edited models. This transaction is therefore beneficial for all parties and fully in-line with our Investing for Growth strategy to focus on establishing leadership positions in our key markets.”
Dr Adrian Hardy, President and CEO of Envigo, added: “Envigo has a strong strategic rationale for this acquisition. We already provide the industry’s broadest range of research models to the global biopharma, academia, government and life science organizations, so we can provide the necessary scale and commercial infrastructure to more broadly market genetically engineered models and associated services. The genetic-modification technologies expertise of the acquired business is an important addition to our portfolio to enable us to further expand the range of products and services available to Envigo customers. We are delighted to welcome the team to the Envigo family and look forward to a strong collaboration with Horizon in future activities.”
Want more of the latest science news straight to your inbox? Become a SelectScience member for free today>>
Related products
Request Quote for All Products
CRISPR Screening Services
CRISPR Screening Services Horizon offers comprehensive CRISPR screening services from screen design and cell line selection to sophisticated bioinformatics analysis of the screen results. Our best-in-class CRISPR KO (knockout), CRISPRi (interference) and CRISPRa (activation) screening platforms can significantly advance our customers’ drug development programs by offering the highest quality and highest confidence in their screening results. Data analysis services, including sample preparation, Next-Gen Sequencing, and hit calling, can be provided for users of Edit-R Lentiviral sgRNA Pooled Screening Libraries. Simply provide whole cell pellets for each of your samples and we’ll do the rest. We can also help with the NGS data analysis and hit calling for data created using the Edit-R Pooled sgRNA Indexing PCR and Sequencing Primer Kits. Types of CRISPR Screen Expertise includes whole-genome and custom targeted drug resistance and sensitivity screens, synthetic lethality target discovery screens and complex phenotypic screens using a FACS-based readout. We have optimized 50+ cell lines for CRISPR screening and have completed over 300 screens to date. We offer a choice of CRISPR screen types depending on the expression effect you require: CRISPR KO screening with complete loss of gene expression provides the maximal window for phenotypic effect and high statistical power for hit discovery CRISPRi screening represses expression rather than completely knocking out the target gene and is ideally suited to study druggability and to evaluate the function of genes that when knocked-out are essential or that are amplified CRISPRa screening amplifies gene expression in its endogenous context and enables for the first time, to study activation-linked responses on a genome-wide level Dual CRISPRi & CRISPRa screening